Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Brent Griffin

Allergy & Immunology Evans, GA Medical Doctor

NPI 1104208743 CMS profile 3063499

340 N Belair Rd, Evans, GA 30809

Open in the dashboard

General payments

$2,055

46 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Griffin of Evans, GA is reported in the CMS Open Payments database as having received $2,055 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $627 18
2024 General $381 13
2023 General $293 8
2022 General $147 2
2021 General $572 3
2020 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Griffin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Brent Griffin were reported at $627. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Brent Griffin Allergy & Immunology median Middle half National median
2019 $0 $378 $115–$1,178 $163
2020 $34 $303 $75–$1,581 $114
2021 $572 $407 $122–$1,475 $132
2022 $147 $357 $120–$1,340 $149
2023 $293 $445 $124–$1,536 $160
2024 $381 $541 $129–$1,763 $164
2025 $627 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Genzyme Corporation $885 11 payments
  2. Regeneron Healthcare Solutions, Inc. $314 10 payments
  3. BioCryst US Sales Co., LLC $179 2 payments
  4. Ionis Pharmaceuticals, Inc. $109 1 payment
  5. GlaxoSmithKline, LLC. $95 3 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $70 3 payments
  7. Teva Pharmaceuticals USA, Inc. $62 1 payment
  8. Pfizer Inc. $49 3 payments
  9. Genentech USA, Inc. $46 2 payments
  10. CSL Behring $36 1 payment
  11. Other $210 9 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,455 44 payments
  2. Grant $500 1 payment
  3. Education $99 1 payment
Products named General payments · program years 2020–2025
  1. DUPIXENT Immunology $373 13 payments
  2. DUPIXENT Immunology And Inflammation $185 4 payments
  3. Orladeyo $179 2 payments
  4. DUPIXENT Inflammation And Immunology $129 6 payments
  5. DAWNZERA $109 1 payment
  6. NUCALA $95 3 payments
  7. Xolair $76 3 payments
  8. CUVITRU $70 3 payments
  9. AirDuo Digihaler $62 1 payment
  10. Andembry $36 1 payment
  11. Other $190 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

124

Median for Internal Medicine: 777

Drug cost

$119,730

Median for Internal Medicine: $73,373

Branded share of claims

16.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 21 $118,177
Azelastine Hcl Generic 23 $778
Ipratropium Bromide Generic 12 $289
Fluticasone Propionate Generic 25 $272
Triamcinolone Acetonide Generic 11 $116
Montelukast Sodium Generic 20 $80
Prednisone Generic 12 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$27,624

Medicare's payments for the services billed

Medicare patients

218

Average age 72

Services billed

2,020

151 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 31%
Chronic kidney disease 24%
Depression 19%
Ischemic heart disease 18%
COPD 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $224
  • Regeneron Healthcare Solutions, Inc. $111
$336 — —
Xolair
  • Genentech USA, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record